Cross-talk between Vitamin D Receptor (VDR)- and Peroxisome Proliferator-activated Receptor (PPAR)-signaling in melanoma cells

Anticancer Research

Volumn 29, Issue 9, 2009, Pages 3647-3658

  Sertznig, Pit ^a   Dunlop, Tom ^b   Seifert, Markus ^a   Tilgen, Wolfgang ^a   Reichrath, Jörg ^a  

^a SAARLAND UNIVERSITY   (Germany)

^b UNIVERSITY OF EASTERN FINLAND   (Finland)

Author keywords

Malignant melanoma; Nuclear receptors; Peroxisome proliferator activated receptors; PPAR; VDR; Vitamin D receptor

Indexed keywords

[2 METHYL 4 [4 METHYL 2 (4 TRIFLUOROMETHYLPHENYL) 5 THIAZOLYLMETHYLTHIO]PHENOXY]ACETIC ACID; BEZAFIBRATE; CALCIDIOL 1 MONOOXYGENASE; CALCITRIOL; DOCOSAHEXAENOIC ACID; LINOLENIC ACID; MESSENGER RNA; PEROXISOME PROLIFERATOR ACTIVATED RECEPTOR; PEROXISOME PROLIFERATOR ACTIVATED RECEPTOR ALPHA; PEROXISOME PROLIFERATOR ACTIVATED RECEPTOR DELTA; PEROXISOME PROLIFERATOR ACTIVATED RECEPTOR GAMMA; PIRINIXIC ACID; VITAMIN D RECEPTOR;

CELL PROLIFERATION; CONFERENCE PAPER; CONTROLLED STUDY; HUMAN; HUMAN CELL; MELANOMA CELL; MOLECULAR INTERACTION; PRIORITY JOURNAL; PROTEIN EXPRESSION; REAL TIME POLYMERASE CHAIN REACTION; SIGNAL TRANSDUCTION;

BASE SEQUENCE; CALCITRIOL; CELL LINE, TUMOR; CELL PROLIFERATION; DNA PRIMERS; HUMANS; MELANOMA; PEROXISOME PROLIFERATOR-ACTIVATED RECEPTORS; RECEPTOR CROSS-TALK; RECEPTORS, CALCITRIOL; SIGNAL TRANSDUCTION;

EID: 68549133281     PISSN: 02507005     EISSN: None     Source Type: Journal    
DOI: None     Document Type: Conference Paper

References (54)

1. Jemal A, Tiwari RC, Murray T, Ghafoor A, Samuels A, Ward E et al: Cancer statistics, 2004. CA Cancer J Clin 54: 8-29, 2004.
2. Eigentler TK, Caroli UM, Radny P and Garbe C: Palliative therapy of disseminated malignant melanoma: a systematic review of 41 randomised clinical trials. Lancet Oncol 4: 748-759, 2003. (Pubitemid 37527210)
3. Hauschild A, Weichenthal M, Balda BR, Becker JC, Wolff HH, Tilgen W et al: Prospective randomized trial of interferon α-2b and interleukin-2 as adjuvant treatment for resected intermediate- and high-risk primary melanoma without clinically detectable node metastasis. J Clin Oncol 21: 2883-2888, 2003. (Pubitemid 46621837)
4. Freudlsperger C, Moll I, Schumacher U and Thies A: Anti-proliferative effect of peroxisome proliferator-activated receptor γ agonists on human malignant melanoma cells in vitro. Anticancer Drugs 17: 325-1323, 2006.
5. Grabacka M, Plonka PM, Urbanska K and Reiss K: Peroxisome proliferator receptor α activation decreases metastatic potential of melanoma cells in vitro via down-regulation of Akt. Clin Cancer Res 12(10): 3028-3036, 2006. (Pubitemid 43837347)
6. Osborne JE and Hutchinson PE: Vitamin D and systemic cancer: Is this relevant to malignant melanoma? Br J Dermatol 147: 197-213, 2002.
7. 3 and its analogs on growth control and tumorigenesis. Front Biosci 6: 820-848, 2001.
8. Demierre MF and Nathanson L: Chemoprevention of melanoma: an unexplored strategy. J Clin Oncol 21: 158-165, 2003.
9. Dellavalle RP, Nicholas MK and Schilling LM: Melanoma chemoprevention: a role for statins or fibrates? Am J Ther 10: 203-210, 2003.
10. Rubins HB, Robins SJ, Collins D et al: Gemfibrozil for the secondary prevention of coronary heart disease in men with low levels of high-density lipoprotein cholesterol. Veterans Affairs High-Density Lipoprotein Cholesterol Intervention Trial Study Group. N Engl J Med 341: 410-418, 1999.
11. Grabacka M, Placha W, Plonka PM et al: Inhibition of melanoma metastases by fenofibrate. Arch Dermatol Res 296: 54-58, 2004.
12. Staels B, Van Tol A, Fruchart JC and Auwerx J: Effects of hypolipidemic drugs on the expression of genes involved in high density lipoprotein metabolism in the rat. Ir J Med Sci 32: 490-498, 1996. (Pubitemid 26237371)
13. Staels B, Dallongeville J, Auwerx J, Schoonjans K, Leitersdorf E and Fruchart JC: Mechanism of action of fibrates on lipid and lipoprotein metabolism. Circulation 98: 2088-2093, 1998. (Pubitemid 28512236)
14. Stumpf WE, Sar M, Reid FA, Tanaka Y and DeLuca HF: Target cells for 1,25-dihydroxyvitamin D3 in intestinal tract, stomach, kidney, skin, pituitary and parathyroid. Science 209: 1189-1190, 1979. (Pubitemid 10159658)
15. Baker AR, McDonnell DP and Hughes M: Cloning and expression of full-length cDNA encoding human vitamin D receptor. Proc Natl Acad Sci USA 85: 3294-3298, 1988. (Pubitemid 18199246)
16. Kliewer SA, Umesono K, Mangelsdorf DJ and Evans RM: Retinoic X receptor interacts with nuclear receptors in retinoic acid, thyroid hormone and vitamin D3 signalling. Nature 355: 446-449, 1992.
17. Evans RM: The steroid and thyroid hormone receptor superfamily. Science 240: 889-895, 1988.
18. 3 on melanoma cell lines in vitro. J Steroid Biochem Mol Biol 89-90: 375-379, 2004. (Pubitemid 38844314)
19. 3 and its analogues. Cell Death Differ 5: 946-952, 1998. (Pubitemid 28510697)
20. 3 and the retinoid CD437 in the induction of human melanoma cell apoptosis. Int J Cancer 81(3): 467-470, 1999. (Pubitemid 29165207)
21. Palmer HG, Gonzalez-Sancho JM, Espada J, Berciano MT, Puig I, Baulida J, Quintanilla M, Cano A, de Herreros AG, Lafarga M and Munoz A: Vitamin D(3) promotes the differentiation of colon carcinoma cells by the induction of E-cadherin and the inhibition of beta-catenin signaling. J Cell Biol 154(2): 369-387, 2001. (Pubitemid 34286147)
22. Palmer HG, Larriba MJ, Garcia JM, Ordonez-Moran P, Pena C, Peiro S, Puig I, Rodriguez R, de la Fuente R, Bernad A, Pollan M, Bonilla F, Gamallo C, de Herreros AG and Munoz A: The transcription factor SNAIL represses vitamin D receptor expression and responsiveness in human colon cancer. Nat Med 10(9): 917-919, 2004. (Pubitemid 39273731)
23. Peinado H, Olmeda D and Cano A: Snail, Zeb and bHLH factors in tumour progression: an alliance against the epithelial phenotype? Nat Rev Cancer 7(6): 415-428, 2007.
24. Bronner-Fraser M: Neural crest cell migration in the developing embryo. Trends Cell Biol 3: 392-397, 1993. (Pubitemid 23315052)
25. Wahli W, Braissant O and Desvergne B: Peroxisome proliferator-activated receptors: transcriptional regulators of adipogenesis, lipid metabolism and more. Chem Biol 2: 261-266, 1995.
26. Desvergne B and Wahli W: PPAR: a key nuclear factor in nutrient/gene interactions? In: Inducible Transcription. Bauerle P (ed.), Birkhäuser, Boston vol1 pp. 142-176, 1995.
27. Chawla A, Repa JJ, Evans RM and Mangelsdorf DJ: Nuclear receptors and lipid physiology: opening the X-files. Science 294: 1866-1870, 2001.
28. Escher P and Wahli W: Peroxisome proliferator-activated receptors: insight into multiple cellular functions. Mutat Res 448: 121-138, 2000. (Pubitemid 30139449)
29. Amri EZ, Bonino F, Ailhaud G, Abumrad NA and Grimaldi PA: Cloning of a protein that mediates transcriptional effects of fatty acids in preadipocytes. Homology to peroxisome proliferator-activated receptors. J Biol Chem 270: 2367-2371, 1995.
30. Desvergne B and Wahli W: Peroxisome proliferator-activated receptors: nuclear control of metabolism. Endocr Rev 20: 649-688, 1999. (Pubitemid 30650602)
31. Braissant O, Foufelle F, Scotto C, Dauca M and Wahli W: Differential expression of peroxisome proliferator-activated receptors (PPARs): tissue distribution of PPAR-α, -β, and -γ in the adult rat. Endocrinology 137: 354-366, 1996.
32. Escher P, Braissant O, Basu-Modak S, Michalik L, Wahli W and Desvergne B: Rat PPARs: quantitative analysis in adult rat tissues and regulation in fasting and refeeding. Endocrinology 142: 4195-4202, 2001. (Pubitemid 32907045)
33. Michalik L, Desvergne B, Basu-Modak S, Tan NS and Wahli W: Nuclear hormone receptors and mouse skin homeostasis: implication of PPARβ. Horm Res 54: 263-268, 2000. (Pubitemid 34701731)
34. Tontonoz P, Hu E, Graves RA, Budavari AI and Spiegelman BM: mPPAR γ 2: tissue-specific regulator of an adipocyte enhancer. Genes Dev 8: 1224-1234, 1994. (Pubitemid 2102252)
35. Chawla A, Schwarz EJ, Dimaculangan DD and Lazar MA: Peroxisome proliferator-activated receptor (PPAR) γ: adipose-predominant expression and induction early in adipocyte differentiation. Endocrinology 135: 798-800, 1994. (Pubitemid 24241266)
36. Tontonoz P, Hu E and Spiegelman BM: Stimulation of adipogenesis in fibroblasts by PPAR γ 2, a lipid-activated transcription factor. Cell 79: 1147-1156, 1994.
37. Fajas L, Auboeuf D, Raspe E, Schoonjans K, Lefebvre AM, Saladin R, Najib J, Laville M, Fruchart JC, Deeb S, Vidal-Puig A, Flier J, Briggs MR, Steals B, Vidal H and Auwerx J: The organization, promoter analysis, and expression of the human PPARy gene. J Biol Chem 272: 18779-18789, 1997. (Pubitemid 27318225)
38. Mansen A, Guardiola-Diaz H, Rafter J, Branting C and Gustafsson JA: Expression of the peroxisome proliferator-activated receptor (PPAR) in the mouse colonic mucosa. Biochem Biophys Res Commun 222: 844-851, 1996. (Pubitemid 26194840)
39. Lefebvre AM, Paulweber B, Fajas L, Woods J, McCary C, Colombel JF, Najib J, Fruchart JC, Datz C, Vidal H, Desreumaux P and Auwerx J: Peroxisome proliferator-activated receptor γ is induced during differentiation of colon epithelium cells. J Endocrinol 162: 331-340, 1999. (Pubitemid 29447426)
40. Greene ME, Blumberg B, McBride OW, Yi HF, Kronquist K, Kwan K, Hsieh L, Greene G and Nimer SD: Isolation of human peroxisome proliferator-activated receptor γ cDNA: expression in hematopoietic cells and chromosomal mapping. Gene Expr 4: 281-299, 1995.
41. Palmer CN, Hsu MH, Griffin KJ, Raucy JL and Johnson EF: Peroxisome proliferator activated receptor-α expression in human liver. Mol Pharmacol 53: 14-22, 1998.
42. Auboeuf D, Rieusset J, Fajas L, Vallier P, Frering V, Riou JP, Steals B, Auwerx J, Laville M and Vidal H: Tissue distribution and quantification of the expression of mRNAs of peroxisome proliferator-activated receptors and liver X receptor-α in humans: no alteration in adipose tissue of obese and NIDDM patients. Diabetes 46: 1319-1327, 1997.
43. Gonzalez FJ: The role of peroxisome proliferator-activated receptor alpha in peroxisome proliferation, physiological homeostasis, and chemical carcinogenesis. Adv Exp Med Biol 422: 109-125, 1997.
44. Gottlicher M, Widmark E, Li Q and Gustafsson JA: Fatty acids activate a chimera of the clofibric acid-activated receptor and the glucocorticoid receptor. Proc Natl Acad Sci USA 89: 4653-4657, 1992.
45. Forman BM, Chen J and Evans RM: Hypolipidemic drugs, polyunsaturated fatty acids, and eicosanoids are ligands for peroxisome proliferator-activated receptors α and δ. Proc Natl Acad Sci USA 94: 4312-4317, 1997. (Pubitemid 27194238)
46. Xu HE, Lambert MH, Montana VG, Parks DJ, Blanchard SG, Brown PJ, Sternbach DD, Lehmann JM, Wisely GB, Willson TM, Kliewer SA and Milburn MV: Molecular recognition of fatty acids by peroxisome proliferator-activated receptors. Mol Cell 3: 397-403, 1999.
47. Berger J and Moller DE: The mechanisms of action of PPARs. Annu Rev Med 53: 409-435, 2002.
48. Bookout AL, Jeong Y, Downes M, Yu RT, Evans RM and Mangelsdorf DJ: Anatomical profiling of nuclear receptor expression reveals a hierarchical transcriptional network. Cell 126: 789-799, 2006. (Pubitemid 44233630)
49. 3 and its nuclear receptor. J Mol Biol 349(2): 248-260, 2005. (Pubitemid 40693747)
50. Carey TE, Takahashi T, Resnick LA, Oettgen HF and Old LJ: Cell surface antigens of human malignant melanoma; mixed hemadsorption assays for humoral immunity to cultured autologous melanoma cells. Proc Natl Acad Sci USA 73: 3278-3282, 1976.
51. 3-responsive and -resistant melanoma cells. Cancer Biol Ther 6(1): 48-55, 2007.
52. Kliewer SA, Xu HE, Lambert MH and Willson TM: Peroxisome proliferator-activated receptors: From genes to physiology. Recent Prog Horm Res 56: 239-263, 2001. (Pubitemid 33733091)
53. Kippenberger S, Loitsch SM, Grundmann-Kollmann M, Simon S, Dang TA, Hardt-Weinelt K, Kaufmann R and Bernd A: Activators of peroxisome proliferator-activated receptors protect human skin from ultraviolet-B-light- induced inflammation. J Invest Dermatol 117: 1430-1436, 2001. (Pubitemid 34032769)
54. Matthaei S, Stumvoll M and Häring HU: Thiazolidinedione (Insulinsensitizer): Neue Aspekte in der Therapie des Diabetes mellitus Typ 2. Dt Ärztebl 98: 912-918, 2001.